Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen

Haemophilia

Volumn 20, Issue 4, 2014, Pages 587-592

  van Veen, J J ^a   Maclean, R M ^a   Hampton, K K ^a   Hamer, A ^b   Makris, M ^a,c  

^a Sheffield Haemophilia and Thrombosis Centre   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Activated prothrombin complex concentrate; Haemophilia A; Inhibitor; rFVIIa; Surgery; Total hip replacement

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; D DIMER; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; NEUTRALIZING ANTIBODY; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ABDOMINAL BLEEDING; ADULT; APPENDECTOMY; ARTICLE; BLEEDING; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY SURGERY; HEMARTHROSIS; HEMATOMA; HEMOPHILIA A; HEMOSTASIS; HUMAN; JOINT SWELLING; KNEE PAIN; MAJOR SURGERY; MALE; MUSCLE BLEEDING; MUSCLE HEMATOMA; ORCHIECTOMY; ORTHOPEDIC SURGERY; PHYSIOTHERAPY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; SURGICAL DRAINAGE; THROMBOCYTE COUNT; TOTAL KNEE REPLACEMENT; TOURNIQUET; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; POSTOPERATIVE PERIOD;

ADULT; ANTIBODIES, NEUTRALIZING; APPENDECTOMY; BLOOD COAGULATION FACTORS; DRUG THERAPY, COMBINATION; FACTOR VIIA; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; POSTOPERATIVE PERIOD; RECOMBINANT PROTEINS;

EID: 84904737231     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12365     Document Type: Article

References (33)

1. Duthie R. Reconstructive surgery and joint replacement. In: The management of musculoskeletal problems in the haemophilias. Oxford: Oxford University Press, 1994: 191-215.
2. Rangarajan S, Austin S, Goddard NJ et al. Consensus recommendations for the use of FEIBA in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia 2013; 19: 294-303.
3. Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 2011; 17: 579-89.
4. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
5. Solimeno LP, Mancuso ME, Pasta G, Santagostino E, Perfetto S, Mannucci PM. Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution. Br J Haematol 2009; 145: 227-34.
6. Wang K, Street A, Dowrick A, Liew S. Clinical outcomes and patient satisfaction following total joint replacement in haemophilia - 23-year experience in knees, hips and elbows. Haemophilia 2012; 18: 86-93.
7. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
8. Gautier P, Alche-Gautier MJ, Coatmelec B et al. Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres. Haemophilia 2002; 8: 674-9.
9. Stephens JM, Joshi AV, Sumner M, Botteman MF. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opin Pharmacother 2007; 8: 1127-36.
10. Green C, de Cock E. Cost-consequences of orthopaedic surgery in haemophilia patients with inhibitors. Value in Health 2001; 4: 467-8.
11. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005; 11(Suppl 1): 11-7.
12. Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin 2008; 24: 753-68.
13. Teitel JM, Carcao M, Lillicrap D et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227-39.
14. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
15. Iorio A, Matino D, D'Amico R, Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2010. Art. No.: CD004449. doi: 10.1002/14651858.CD004449.pub3.
16. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microgram/kg dose rFVIIa vs. standard 90 microgram/kg dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
17. Collins PW, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013; 160: 153-70.
18. Knight C, Dano AM, Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther 2009; 26: 68-88.
19. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
20. Giangrande PL, Wilde JT, Madan B et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009; 15: 501-8.
21. Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V, Hernandez-Navarro F. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia 2007; 13: 613-9.
22. Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high-responder haemophilia patients. Haemophilia 2004; 10(Suppl 2): 46-9.
23. Medicines and Healthcare products Regulatory Agency. MHRA UKPAR - FEIBA 500 U and 1000 U powder and solvent for solution for infusion PL 00215/0021-22. Available at http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con014534.pdf Accessed August 8, 2013.
24. Negrier C, Lienhart A, Numerof R et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia 2013; 19: e143-50.
25. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142: 889-903.
26. van Veen JJ, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. Int J Lab Hematol 2009; 31: 189-98.
27. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
28. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
29. Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA(R)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A-a two-centre experience. Haemophilia 2012; 18: 544-9.
30. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
31. Gringeri A, Fischer K, Karafoulidou A, Klamroth R, Lopez-Fernandez MF, Mancuso E. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17: 630-5.
32. Schneiderman J, Rubin E. Nugent DJ, YOUNG G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
33. Ingerslev J, Sorensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 2011; 155: 256-62.